Sunday, November 22, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Press releaseGlobeNewswire· April 19, 2026

Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

View original at globenewswire.com
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026 STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO…
Opening lines of the source · GlobeNewswire · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Initial results from STRO-004 Phase 1 study expected in mid-2026

    60% confidence
  • Exploratory biomarker analyses suggest potential for STRO-004 combination studies addressing specific indications in either early or late lines of treatment

    60% confidence
  • STRO-004's favorable tolerability and pharmacokinetic profile are expected to enable increased drug exposure and payload delivery, supporting superior depth and durability of response in the clinic

    60% confidence
  • STRO-004 preclinical data underscore the potential of next-generation ADCs to drive meaningful activity across multiple solid tumors

    60% confidence
  • Preclinical data strengthen confidence in STRO-004's potential across indications and underscore platform versatility to generate differentiated ADCs across many targets and payloads

    60% confidence

Cited in these Via News reports